Valbenazine Oral Capsule
ApprovedWithdrawn 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tardive Dyskinesia
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Trial Timeline
Jan 1, 2025 → Feb 1, 2027
NCT ID
NCT06107829About Valbenazine Oral Capsule
Valbenazine Oral Capsule is a approved stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06107829. Target conditions include Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities.
What happened to similar drugs?
2 of 6 similar drugs in Tardive Dyskinesia were approved
Approved (2) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06107829 | Approved | Withdrawn |
| NCT05207085 | Phase 2 | Recruiting |
Competing Products
13 competing products in Tardive Dyskinesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sarizotan | Merck | Pre-clinical | 18 |
| levetiracetam + placebo | UCB | Phase 3 | 40 |
| Valbenazine | Neurocrine Biosciences | Phase 1 | 18 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 32 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 32 |
| NBI-98854 | Neurocrine Biosciences | Phase 3 | 37 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 40 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 32 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 3 | 37 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 37 |
| NBI-98854 + NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 32 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Approved | 40 |
| NBI-1065890 + Placebo | Neurocrine Biosciences | Phase 2 | 39 |